Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Heymach

Showing results (11-20 of 72) with videos related to

Pageof 8
Sort By:
Science (New York, N.Y.)|July 30, 2002
Antiangiogenic therapy and p53Timothy Browder, Judah Folkman, Philip Hahnfeldt, et al.
Clinical Lung Cancer|February 5, 2014
Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesotheliomaAnne S Tsao, Nusrat Harun, J Jack Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|March 20, 2023
Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectivesMartin Reck, Sanjay Popat, Christian Grohé, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivoWenhong Ren, Borys Korchin, Quan-Sheng Zhu, et al.
JCO Oncology Practice|June 17, 2020
What Do Patients With Non-Small-Cell Lung Cancer Experience? Content Domain for the MD Anderson Symptom Inventory for Lung CancerMeagan S Whisenant, Loretta A Williams, Araceli Garcia Gonzalez, et al.
Heliyon|July 3, 2023
AI in drug discovery and its clinical relevanceRizwan Qureshi, Muhammad Irfan, Taimoor Muzaffar Gondal, et al.
Molecular Cancer Therapeutics|February 5, 2008
Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endotheliumPaul Beaudry, Monique Nilsson, Matthew Rioth, et al.
Frontiers in Nephrology|September 7, 2023
Case Report: Immune checkpoint inhibitor-induced multiorgan vasculitis successfully treated with rituximabSehrish Qureshi, Naszrin Arani, Vishnu Parvathareddy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2011
Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitroDaisuke Sano, Fumihiko Matsumoto, David R Valdecanas, et al.
Cancer Medicine|March 11, 2024
Personal history of cancer as a risk factor for second primary lung cancer: Implications for lung cancer screeningSara Nofal, Jiangong Niu, Paul Resong, et al.
Pageof 8

Showing results (11-20 of 72) with videos related to

Sort By:
Pageof 8
Science (New York, N.Y.)|July 30, 2002
Antiangiogenic therapy and p53Timothy Browder, Judah Folkman, Philip Hahnfeldt, et al.
Clinical Lung Cancer|February 5, 2014
Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesotheliomaAnne S Tsao, Nusrat Harun, J Jack Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|March 20, 2023
Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectivesMartin Reck, Sanjay Popat, Christian Grohé, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivoWenhong Ren, Borys Korchin, Quan-Sheng Zhu, et al.
JCO Oncology Practice|June 17, 2020
What Do Patients With Non-Small-Cell Lung Cancer Experience? Content Domain for the MD Anderson Symptom Inventory for Lung CancerMeagan S Whisenant, Loretta A Williams, Araceli Garcia Gonzalez, et al.
Heliyon|July 3, 2023
AI in drug discovery and its clinical relevanceRizwan Qureshi, Muhammad Irfan, Taimoor Muzaffar Gondal, et al.
Molecular Cancer Therapeutics|February 5, 2008
Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endotheliumPaul Beaudry, Monique Nilsson, Matthew Rioth, et al.
Frontiers in Nephrology|September 7, 2023
Case Report: Immune checkpoint inhibitor-induced multiorgan vasculitis successfully treated with rituximabSehrish Qureshi, Naszrin Arani, Vishnu Parvathareddy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2011
Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitroDaisuke Sano, Fumihiko Matsumoto, David R Valdecanas, et al.
Cancer Medicine|March 11, 2024
Personal history of cancer as a risk factor for second primary lung cancer: Implications for lung cancer screeningSara Nofal, Jiangong Niu, Paul Resong, et al.
Pageof 8